ALX-215-001-R100
antibody from Enzo Life Sciences
Targeting: MAPT
DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-215-001-R100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-215-001-R100, RRID:AB_2050501
- Product name
- [pSer262]Tau polyclonal antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Epitope affinity-purified. Negatively preadsorbed by non-phosphorylated immunogen peptide.
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 100 μl
- Storage
- -20°C
- Handling
- For maximum product recovery after thawing, centrifuge the vial before opening the cap. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20¡C.
Submitted references Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.
Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, Gong CX
The Journal of biological chemistry 2005 Jan 21;280(3):1790-6
The Journal of biological chemistry 2005 Jan 21;280(3):1790-6
Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
Liu F, Iqbal K, Grundke-Iqbal I, Gong CX
FEBS letters 2002 Oct 23;530(1-3):209-14
FEBS letters 2002 Oct 23;530(1-3):209-14
Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, Gong CX
FEBS letters 2002 Feb 13;512(1-3):101-6
FEBS letters 2002 Feb 13;512(1-3):101-6
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Peptide competition. Only the phosphopetide corresponding to tau [pS262] blocks the antibody signal, demonstrating the specificity of the antibody. Tau [pS262] phophorylation is induced by the addition of PKA. Method: Human recombinant tau untreated (lane 1) or treated with PKA (36µg per µg tau) for 45 min and added to background extracts was resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was blocked with a 5% BSA-TBST buffer overnight at 4¡C, then incubated with PAb to Tau (phosphorylated) (pSer262) (Prod. No. ALX-215-001) for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 2), the non-phosphopeptide corresponding to the phosphopeptide immunogen (3), a generic phosphoserine-containing peptide (4), or the phosphopeptide immunogen (5). After washing, the membrane was incubated with goat F(ab')2 anti-rabbit IgG HRP conjugate and signals were detected using the Pierce SuperSignalTM method.